Safety and efficacy of melatonin supplementation as an add-on treatment for infantile epileptic spasms syndrome: A randomized, placebo-controlled, double-blind trial.
Study Goal
The researchers aimed to evaluate the efficacy and safety of melatonin as an add-on treatment for infantile epileptic spasms syndrome (IESS) when combined with ACTH and magnesium sulfate.
Results Summary
The abstract does not provide specific results regarding melatonin's effects on IESS.
Population
Infants and children aged 3 months to 2 years with a primary diagnosis of IESS.
Effective Dosage
Not available
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
melatonin as an add-on treatment | neutral | efficacy and safety | Participants aged 3 months to 2 years with a primary diagnosis of infantile epileptic spasms syndrome (IESS) | - | to assess the efficacy and safety | #1 |
adrenocorticotrophic hormone (ACTH) | neutral | - | Participants aged 3 months to 2 years with a primary diagnosis of infantile epileptic spasms syndrome (IESS) | - | received | #2 |
magnesium sulfate (MgSO4) | neutral | - | Participants aged 3 months to 2 years with a primary diagnosis of infantile epileptic spasms syndrome (IESS) | - | received | #3 |
This was a prospective, randomized, double-blind, single-center placebo-controlled trial to assess the efficacy and safety of melatonin as an add-on treatment for infantile epileptic spasms syndrome (IESS). Participants aged 3 months to 2 years with a primary diagnosis of IESS were recruited and assigned to two groups in a 1:1 ratio. Both treatment groups received a combination of adrenocorticotrophic hormone (ACTH) and magnesium sulfate (MgSO